Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
Status:
NOT_YET_RECRUITING
Trial end date:
2028-05-31
Target enrollment:
Participant gender:
Summary
This study is being done to find out if administering CytoGam after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
Phase:
PHASE4
Details
Lead Sponsor:
Camille N. Kotton, MD
Collaborators:
Kamada, Ltd. University of Texas Southwestern Medical Center